FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212884787> ?p ?o ?g. }

• W4212884787 endingPage "e2146798" @default.
• W4212884787 startingPage "e2146798" @default.
• W4212884787 abstract "The incidence of infection during SARS-CoV-2 viral waves, the factors associated with infection, and the durability of antibody responses to infection among Canadian adults remain undocumented.To assess the cumulative incidence of SARS-CoV-2 infection during the first 2 viral waves in Canada by measuring seropositivity among adults.The Action to Beat Coronavirus study conducted 2 rounds of an online survey about COVID-19 experience and analyzed immunoglobulin G levels based on participant-collected dried blood spots (DBS) to assess the cumulative incidence of SARS-CoV-2 infection during the first and second viral waves in Canada. A sample of 19 994 Canadian adults (aged ≥18 years) was recruited from established members of the Angus Reid Forum, a public polling organization. The study comprised 2 phases (phase 1 from May 1 to September 30, 2020, and phase 2 from December 1, 2020, to March 31, 2021) that generally corresponded to the first (April 1 to July 31, 2020) and second (October 1, 2020, to March 1, 2021) viral waves.SARS-CoV-2 immunoglobulin G seropositivity (using a chemiluminescence assay) by major geographic and demographic variables and correlation with COVID-19 symptom reporting.Among 19 994 adults who completed the online questionnaire in phase 1, the mean (SD) age was 50.9 (15.4) years, and 10 522 participants (51.9%) were female; 2948 participants (14.5%) had self-identified racial and ethnic minority group status, and 1578 participants (8.2%) were self-identified Indigenous Canadians. Among participants in phase 1, 8967 had DBS testing. In phase 2, 14 621 adults completed online questionnaires, and 7102 of those had DBS testing. Of 19 994 adults who completed the online survey in phase 1, fewer had an educational level of some college or less (4747 individuals [33.1%]) compared with the general population in Canada (45.0%). Survey respondents were otherwise representative of the general population, including in prevalence of known risk factors associated with SARS-CoV-2 infection. The cumulative incidence of SARS-CoV-2 infection among unvaccinated adults increased from 1.9% in phase 1 to 6.5% in phase 2. The seropositivity pattern was demographically and geographically heterogeneous during phase 1 but more homogeneous by phase 2 (with a cumulative incidence ranging from 6.4% to 7.0% in most regions). The exception was the Atlantic region, in which cumulative incidence reached only 3.3% (odds ratio [OR] vs Ontario, 0.46; 95% CI, 0.21-1.02). A total of 47 of 188 adults (25.3%) reporting COVID-19 symptoms during phase 2 were seropositive, and the OR of seropositivity for COVID-19 symptoms was 6.15 (95% CI, 2.02-18.69). In phase 2, 94 of 444 seropositive adults (22.2%) reported having no symptoms. Of 134 seropositive adults in phase 1 who were retested in phase 2, 111 individuals (81.8%) remained seropositive. Participants who had a history of diabetes (OR, 0.58; 95% CI, 0.38-0.90) had lower odds of having detectable antibodies in phase 2.The Action to Beat Coronavirus study found that the incidence of SARS-CoV-2 infection in Canada was modest until March 2021, and this incidence was lower than the levels of population immunity required to substantially reduce transmission of the virus. Ongoing vaccination efforts remain central to reducing viral transmission and mortality. Assessment of future infection-induced and vaccine-induced immunity is practicable through the use of serial online surveys and participant-collected DBS." @default.
• W4212884787 created "2022-02-24" @default.
• W4212884787 creator A5000302475 @default.
• W4212884787 creator A5000457974 @default.
• W4212884787 creator A5001948223 @default.
• W4212884787 creator A5006671308 @default.
• W4212884787 creator A5007084476 @default.
• W4212884787 creator A5009024370 @default.
• W4212884787 creator A5010233334 @default.
• W4212884787 creator A5010311013 @default.
• W4212884787 creator A5011554906 @default.
• W4212884787 creator A5011981202 @default.
• W4212884787 creator A5013575325 @default.
• W4212884787 creator A5016399385 @default.
• W4212884787 creator A5017234555 @default.
• W4212884787 creator A5024524013 @default.
• W4212884787 creator A5024925846 @default.
• W4212884787 creator A5027221498 @default.
• W4212884787 creator A5031528165 @default.
• W4212884787 creator A5032964922 @default.
• W4212884787 creator A5036469759 @default.
• W4212884787 creator A5038703485 @default.
• W4212884787 creator A5040759446 @default.
• W4212884787 creator A5041318257 @default.
• W4212884787 creator A5041519561 @default.
• W4212884787 creator A5042275901 @default.
• W4212884787 creator A5044271353 @default.
• W4212884787 creator A5045236420 @default.
• W4212884787 creator A5046616377 @default.
• W4212884787 creator A5051795356 @default.
• W4212884787 creator A5057041222 @default.
• W4212884787 creator A5058758557 @default.
• W4212884787 creator A5061495037 @default.
• W4212884787 creator A5061896835 @default.
• W4212884787 creator A5061974710 @default.
• W4212884787 creator A5063629259 @default.
• W4212884787 creator A5065378357 @default.
• W4212884787 creator A5066059215 @default.
• W4212884787 creator A5067601916 @default.
• W4212884787 creator A5068337416 @default.
• W4212884787 creator A5072828467 @default.
• W4212884787 creator A5074819890 @default.
• W4212884787 creator A5074895419 @default.
• W4212884787 creator A5077312829 @default.
• W4212884787 creator A5078976579 @default.
• W4212884787 creator A5081242070 @default.
• W4212884787 creator A5085592014 @default.
• W4212884787 creator A5085839891 @default.
• W4212884787 creator A5086907244 @default.
• W4212884787 creator A5089165397 @default.
• W4212884787 creator A5082551802 @default.
• W4212884787 creator A9999999999 @default.
• W4212884787 date "2022-02-16" @default.
• W4212884787 modified "2023-10-03" @default.
• W4212884787 title "Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults" @default.
• W4212884787 cites W1599441843 @default.
• W4212884787 cites W1994767881 @default.
• W4212884787 cites W2811157820 @default.
• W4212884787 cites W2980536877 @default.
• W4212884787 cites W3020177603 @default.
• W4212884787 cites W3040552450 @default.
• W4212884787 cites W3042345249 @default.
• W4212884787 cites W3064705445 @default.
• W4212884787 cites W3082342835 @default.
• W4212884787 cites W3082955665 @default.
• W4212884787 cites W3083147446 @default.
• W4212884787 cites W3087248341 @default.
• W4212884787 cites W3092050672 @default.
• W4212884787 cites W3093496117 @default.
• W4212884787 cites W3095683209 @default.
• W4212884787 cites W3108096807 @default.
• W4212884787 cites W3110738325 @default.
• W4212884787 cites W3112390401 @default.
• W4212884787 cites W3126981244 @default.
• W4212884787 cites W3165024804 @default.
• W4212884787 cites W3169047476 @default.
• W4212884787 cites W3174875956 @default.
• W4212884787 cites W3183525205 @default.
• W4212884787 cites W3201408162 @default.
• W4212884787 cites W3205738665 @default.
• W4212884787 cites W3209985967 @default.
• W4212884787 cites W4205829018 @default.
• W4212884787 cites W4241677211 @default.
• W4212884787 cites W4256120195 @default.
• W4212884787 doi "https://doi.org/10.1001/jamanetworkopen.2021.46798" @default.
• W4212884787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35171263" @default.
• W4212884787 hasPublicationYear "2022" @default.
• W4212884787 type Work @default.
• W4212884787 citedByCount "16" @default.
• W4212884787 countsByYear W42128847872021 @default.
• W4212884787 countsByYear W42128847872022 @default.
• W4212884787 countsByYear W42128847872023 @default.
• W4212884787 crossrefType "journal-article" @default.
• W4212884787 hasAuthorship W4212884787A5000302475 @default.
• W4212884787 hasAuthorship W4212884787A5000457974 @default.
• W4212884787 hasAuthorship W4212884787A5001948223 @default.
• W4212884787 hasAuthorship W4212884787A5006671308 @default.
• W4212884787 hasAuthorship W4212884787A5007084476 @default.

• next